PROCEPT BioRobotics Corp: A Look at Their 2023 Annual Report

Welcome to a straightforward summary of PROCEPT BioRobotics Corp's latest annual report. We'll explore the company's activities, business performance, and what these insights could mean for investors, all presented in clear, accessible language.

This report details their performance for the fiscal year ending December 31, 2023.

Business Overview

PROCEPT BioRobotics is a medical device company dedicated to advancing prostate health. The company developed the innovative AquaBeam Robotic System, which performs Aquablation therapy – a minimally invasive procedure to treat benign prostatic hyperplasia (BPH). PROCEPT BioRobotics aims to offer a safe, effective, and lasting treatment for men with BPH, thereby enhancing their quality of life.

As a "large accelerated filer" with the SEC, PROCEPT BioRobotics is a substantial company in its market, meaning it has a public market value of at least $700 million. Specifically, the market value of its publicly traded shares reached approximately $3.2 billion as of June 30, 2023. The company also had about 56.4 million shares of common stock outstanding as of February 19, 2024.

Financial Performance

Here are the key financial highlights from 2023:

• Revenue Growth: The company generated strong revenue of $120 million in 2023, a significant 45% increase over the previous year. Increased sales of the AquaBeam Robotic System and greater use of their consumables primarily drove this growth.
• Net Loss: PROCEPT BioRobotics reported a net loss of $70 million for the year, or -$1.25 per share. This reflects the company's continued heavy investment in expansion, funding research and development, and bolstering sales and marketing efforts to broaden market adoption.

Risk Factors

Like any growing medical device company, PROCEPT BioRobotics faces specific risks. Investors should consider factors such as:

• Regulatory Approvals: The continuous need for regulatory clearances and approvals for new products or market expansions.
• Market Adoption: How quickly urologists adopt Aquablation therapy and how readily insurance providers reimburse for it.
• Competition: The competitive environment from both established and new BPH treatments.
• Manufacturing & Supply Chain: Potential disruptions in the company's ability to produce and deliver its systems and consumables.

Management's Discussion and Analysis (MD&A) Highlights

Beyond the financial numbers, management emphasized several key operational and strategic achievements:

• Global Expansion: The company expanded its global presence, installing 150 AquaBeam Robotic Systems worldwide by the end of 2023, a significant increase from 100 systems in 2022.
• Procedure Growth: The number of Aquablation procedures performed globally soared to over 15,000 in 2023, showcasing growing confidence in the technology from both physicians and patients.
• Commercial Investment: PROCEPT BioRobotics strategically invested in expanding its sales and marketing teams, especially in key international markets, to boost awareness and adoption of Aquablation therapy.
• Clinical Evidence: The company continued to build a strong body of clinical evidence, supporting the long-term effectiveness and safety of Aquablation therapy – a critical factor for market entry and insurance coverage.
• Investment in Growth: The reported net loss reflects substantial investments in research and development to enhance the AquaBeam system and broaden its applications. It also includes increased selling, general, and administrative expenses, which support commercial expansion and market development.

Financial Health

• Cash Position: The company maintains a strong cash position, concluding the year with approximately $250 million in cash, cash equivalents, and marketable securities. This provides a solid foundation for future operations and growth initiatives.
• Debt: As of December 31, 2023, the company reported no significant long-term debt. It primarily relies on equity financing and its cash reserves to fund operations and growth.

Future Outlook

Looking ahead, PROCEPT BioRobotics plans to accelerate the global adoption of Aquablation therapy, expand its clinical data, and optimize commercial execution to achieve sustainable growth and profitability. The company aims to continue innovating in prostate health, using its robotic platform to meet unmet patient needs. PROCEPT BioRobotics typically offers financial guidance for the upcoming fiscal year, detailing expected revenue ranges and key strategic priorities for investors.

Competitive Position

PROCEPT BioRobotics holds a strong competitive position, largely thanks to its proprietary AquaBeam Robotic System and Aquablation therapy. This system offers a unique, minimally invasive, and highly effective treatment for BPH. The company's key competitive advantages include:

• A robust portfolio of intellectual property protecting its technology.
• Extensive clinical data demonstrating superior outcomes compared to traditional treatments.
• A growing installed base of systems.

While operating in a competitive medical device market, PROCEPT BioRobotics differentiates itself through its innovative robotic platform and a strong focus on patient outcomes, aiming to establish Aquablation therapy as a standard of care.